Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

rials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of Micromet's product candidate
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... GERMANY (PRWEB) May 26, 2015 ... R. Grace & Co. (NYSE: GRA) announces that ... good manufacturing practice (GMP) certification from EXCiPACT™, an ... of pharmaceutical excipients. , All three ... of pharmaceutical grade excipient silica gels have now ...
(Date:5/26/2015)... und HILDEN, Deutschland, May 26, 2015 /PRNewswire/ ... ®   ermöglicht klinischen ... Erstellung dazugehöriger Berichte; Vorstellung auf den Konferenzen ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... von QIAGEN Clinical Insight ® (QCI™) ...
(Date:5/26/2015)... 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced ... will provide an update on the progress of Sangamo,s ZFP ... company,s business strategy at 1:30pm ET on Monday, June 1, ... is being held in New York, NY ... may be accessed via a link on the Sangamo BioSciences ...
(Date:5/26/2015)...  Alere Inc. (NYSE: ALR ) (the "Company") announced ... file its Quarterly Report on Form 10-Q for the three ... received a notice from the New York Stock Exchange (the ... NYSE,s continued listing requirements under the timely filing criteria established ... The reason for the delay relates to Company,s ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... members help guide non-profit on path to cure ... Project, a Minnesota,non-profit organization created to expedite the ... attracted two well-known experts to its,Board of Directors: ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b ), Steven D. ...
... 16 Celator Pharmaceuticals today,announced that John Bennett, ... the BIO Business Forum during the Biotechnology Industry,Organization ... will,provide a corporate overview and an update on ... on Wednesday, June 18,2008 at 3:30 PDT in ...
... NovaVision today announced,the appointment of Rudy Mazzocchi as ... is responsible for leveraging the company,s novel,technology to ... patients with,impaired vision have access to NovaVision(R) Vision ... expertise bringing new medical technologies,and devices to market ...
Cached Biology Technology:Spring Point Project Names New Members to Board of Directors 2NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 2NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 3
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... rates are concentrated in the northern part of the ... according to a report in Cancer Epidemiology, Biomarkers ... for Cancer Research. Ahmedin Jemal, D.V.M., Ph.D., vice ... said the decrease in death rates ranged from about ...
... global cooling and warming over the past few million ... they do today, according to a new study by ... The researchers, who analyzed California gray whale ( Eschrichtius ... 120,000 years, also found evidence to support the idea ...
... Move over, boy bands of Americathere,s a new ... Middle School in San Diego, California, entered The Christopher ... (STEM) program that challenges middle-school students to identify a ... Taking a cue from the popular group the Backstreet ...
Cached Biology News:Southern US states lag in reducing death rates from colorectal cancer 2Gray whales likely survived the Ice Ages by changing their diets 2Gray whales likely survived the Ice Ages by changing their diets 3Gray whales likely survived the Ice Ages by changing their diets 4Gray whales likely survived the Ice Ages by changing their diets 5Middle-school students educate community on proper computer posture 2
Request Info...
... is ideal for both radioactive and nonradioactive ... Provides five pre-mixed nucleotide solutions for ... >10 8 cpm/g control DNA using ... the performance of the system Labels ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: